Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
- Average Annual Pay for PMDA Staffers at 7.7 Million Yen in FY2021
June 29, 2022
- MHLW Drafts Guidelines on Development of Recombinant Viral Vaccines
June 29, 2022
- Safety of Emergency Approval Products to Be Monitored with RMP: Official
June 27, 2022
- MHLW Panel OKs 56 More Health Damage Claims for COVID-19 Vaccines
June 27, 2022
- Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
June 27, 2022
- PMDA Reviewing Safety Risks for Imfinzi and Bavencio
June 27, 2022
- Health Minister Visits Takeda Manufacturing Site for Novavax Jab, Stresses Need to Handle Diverse Modalities in Japan
June 24, 2022
- Japan Logs 496 Pharma Product Recalls in FY2021; Self-Inspections, COVID Drive Surge
June 24, 2022
- Industry Groups Seek Financial Aid for Securing Pandemic Response Supplies
June 23, 2022
- Pharma-Backed Upper House Candidates Kick Off Campaigning for July 10 Poll
June 23, 2022
- Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
- Takashi Yasukawa Named Pharmaceutical Management Director
June 22, 2022
- Govt Panel Agrees to Add Xofluza to Flu Drug Stockpile
June 22, 2022
- Kazuhiro Oshima Tapped as Vice Health Minister, Katsufumi Jo as First Councilor for Pharma Industry Promotion
June 22, 2022
- Pemigatinib, Azacitidine, TAK-611 Get Orphan Tag in Japan
June 22, 2022
- Health Minister Defends Govt Purchase Pact for Shionogi’s COVID Pill
June 21, 2022
- Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
June 21, 2022
- MHLW Wants to Boost Preparedness with Proposed Pandemic Response Division: Minister
June 20, 2022
- PMDA Clears All Its Review Targets, Processed Relief Claims at Record Speed in FY2021
June 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…